Genient Technologies Showcases DEEPCheck® and BioSpeedy Solutions at MahaMicroCon 2025 in Mumbai

Genient Technologies participated in MahaMicroCon 2025 held at Tata Memorial Hospital, Mumbai, where the company showcased its advanced solutions in clinical sequencing, molecular diagnostics, multiplexing, sepsis testing, and antimicrobial resistance (AMR) diagnostics.

At Booth 31, Genient Technologies presented innovative infectious disease solutions designed to support faster diagnosis, accurate detection, and clinically relevant treatment decisions. The company’s featured portfolio included DEEPCheck® Sequencing for HIV, HBV, HCV, CMV, and MTB drug resistance testing and genotyping, along with BioSpeedy solutions for rapid sepsis diagnostics and AMR detection.

Industry Engagement and Scientific Collaboration

MahaMicroCon 2025 provided a valuable platform for engagement with microbiologists, clinicians, laboratory specialists, researchers, and healthcare industry professionals. The conference enabled meaningful discussions around the future of precision diagnostics, infectious disease testing, genomics, and microbiology innovation in India.

Genient Technologies also thanked the organisers of MahaMicroCon 2025 for hosting a well-curated scientific forum that encouraged collaboration across healthcare, research, and diagnostic innovation.

Key Solutions Presented at MahaMicroCon 2025

• DEEPCheck® Sequencing: Drug resistance and genotyping solutions for HIV, HBV, HCV, CMV, and MTB.
• BioSpeedy: Rapid sepsis and antimicrobial resistance diagnostics enabling faster targeted treatment.
• Clinical Focus: Infectious disease diagnostics, microbiology testing, molecular diagnostics, and precision medicine.

Through its presence at MahaMicroCon 2025, Genient Technologies reaffirmed its commitment to advancing molecular diagnostics, clinical genomics, infectious disease solutions, and precision medicine for healthcare providers and laboratories across India.